STAT Plus: Pharmalittle: Guardant’s blood test could replace biopsy; Medicare boosts CAR-T coverage

Good morning. Elizabeth Cooney here, filling in for Ed Silverman this week as he makes those daydreams of vacation plans come true. Here’s what we’re watching today from Boston HQ:

Guardant Health has published results saying its blood test could replace biopsy for rare cancer treated by Keytruda, STAT reports. Currently, identifying such cancers, called MSI-High, for “microsatellite instable-high,” requires examining a tumor that had been surgically removed. Merck’s (MRK) Keytruda is approved to treat tumors that appear anywhere in the body, but are marked with a specific genetic signature.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Pharmalittle: Guardant’s blood test could replace biopsy; Medicare boosts CAR-T coverage »